ALK and large cell neuroendocrine carcinoma: Actionable mutations, like EGFR mutations or anaplastic lymphoma kinase (ALK) fusions, are exceedingly rare, with a frequency of < 5% in LCNEC and even lower in SCLC [7, 8].